<DOC>
	<DOC>NCT01921712</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of PUR0200. In addition, the study will look at the blood levels of different doses of PUR0200 and their affect on lung function in COPD patients.</brief_summary>
	<brief_title>A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients</brief_title>
	<detailed_description>This is a multi-center, 2-part, pharmacokinetic (PK), pharmacodynamic (PD) effect, safety and tolerability study of single doses of PUR0200.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Key A clinical diagnosis of moderate to severe COPD according to the following criteria: Current or exsmokers with at least 10 packyear smoking history Postbronchodilator FEV1 &gt;/= 35% and &lt;/= 80% of predicted normal value Postbronchodilator FEV1/FVC (forced vital capacity) ratio &lt;0.70 Postbronchodilator improvement in FEV1 &gt;/= 100 mL Key Current evidence or recent history of clinically significant or unstable disease (other than COPD) Current diagnosis of asthma Presence of history of clinically significant allergy requiring treatment COPD exacerbation within 6 weeks Use of daily oxygen therapy &gt; 10 hours Thoracotomy with pulmonary resection Use of systemic steroids within 3 months Lower respiratory tract infection within 30 days Upper respiratory tract infection within 30 days requiring treatment with antibiotics History of tuberculosis, bronchiectasis, or other nonspecific pulmonary disease Prolonged corrected QT (QTc) interval &gt;450 msec males and &gt;470 msec females, or history of long QT syndrome</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
</DOC>